^
Association details:
| Biomarker: | BCOR mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
THE IMPACT OF MUTATIONAL LOAD (VAF) DETECTED IN THE TP53, EZH2, U2AF1, WT1, FLT3 AND SF3B1 GENES WAS IDENTIFIED AS AN INDEPENDENT PROGNOSTIC MARKER FOR OS OR RFS IN A COHORT OF 497 CASES WITH AML
Published date:
05/12/2021
Excerpt:
The mutational profile at diagnosis was identified by NGS (Ion Torrent System), using a panel of 41 genes involved in myeloid pathologies...BCOR….Finally, in patients treated with low-dose cytarabine, TP53 is associated with worse OS and a higher mutational load of TP53 or mutations in the BCOR gene are associated with a worse RFS.
